Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Abbott Laboratories (ABT) Stock Forecast (2026) - clearank.com

AI-generated analysis

📈 Abbott Laboratories beat Q2 2026 EPS estimates by 2.34%, reporting $1.31 per share versus the $1.28 consensus, leading to a 1.87% stock price increase.

📈 The company reported 13% revenue growth in Q2 2026, significantly outpacing the Healthcare sector median of 8.1% and highlighting strong competitive positioning.

📉 Insiders have sold $48.6 million worth of shares versus $4.4 million in purchases, indicating a net seller position that could signal a lack of confidence in near-term stock appreciation.

📉 The stock is trading below its 50-day moving average of $106.19 and 200-day moving average of $105.08, exhibiting an oversold RSI of 23.

🎯 Wall Street's consensus target price for ABT is $120.00 across 27 analysts, while CleaRank Financial AI rates it a Buy with a fair value of $103.00.

📉 Historical data shows a $10,000 investment in ABT in September 2016 would be worth about $24,478 today, compared to $35,293 for the S&P 500 benchmark.

🔮 CleaRank's Monte Carlo simulation projects a base case price near $141 for ABT by 2030, representing a 1.4x return over four years from current levels.

⚠️ The downside path in simulations ends near $76.04, assuming no dividends are reinvested and based on historical volatility and drift.

Bullish Signals
  • Abbott Laboratories beat Q2 2026 EPS estimates by 2.34%, reporting $1.31 per share versus the $1.28 consensus, leading to a 1.87% stock price increase.
  • The company reported 13% revenue growth in Q2 2026, significantly outpacing the Healthcare sector median of 8.1%, highlighting strong competitive positioning and market demand.
Risk Factors
  • Insiders have sold $48.6 million worth of shares versus $4.4 million in purchases, indicating a net seller position that could signal a lack of confidence in near-term stock appreciation.
  • The stock is trading below its 50-day moving average of $106.19 and 200-day moving average of $105.08, exhibiting an oversold RSI of 23 which suggests potential for further price declines before recovery.
Full Analysis
As of September 21, 2026, Abbott Laboratories (ABT) is trading at $102.38, which is below its 50-day moving average of $106.19 and the Wall Street consensus target of $120.00 set by 27 analysts. The stock exhibits an RSI of 23, indicating it is in oversold territory according to CleaRank Financial AI, which rates the stock a Buy with a fair value of $103.00. Financially, Abbott Laboratories demonstrated strong operational execution in Q2 2026 by beating EPS estimates by 2.34%, reporting $1.31 per share against expectations of $1.28. This beat resulted in a 1.87% stock price increase. Additionally, the company reported 13% revenue growth, significantly outpacing the Healthcare sector median of 8.1%, which highlights its competitive positioning and market demand. Despite positive earnings, insider activity shows a net seller position with $48.6 million in share sales versus only $4.4 million in purchases, potentially signaling a lack of confidence in near-term appreciation. Long-term simulations project ABT could reach approximately $141 by 2030 in the base case, though historical performance since 2016 has lagged behind the S&P 500 benchmark. Analysts and technical indicators suggest potential for further price declines before a significant recovery due to the stock trading below key moving averages. The article notes that while the company shows operational strength, the insider selling and technical oversold conditions present mixed signals for immediate investment strategy.